ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting

    Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry

    Nancy A. Shadick1, Michael E Weinblatt1, Christine K Iannaccone2, Michelle Frits3, Tigwa Davis4, Christopher Young4, David H. Collier5, Mahdi Gharaibeh5 and Bradley S. Stolshek6, 1Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Health Analytics, LLC, Columbia, MD, 5Amgen Inc., Thousand Oaks, CA, 6Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
  • Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting

    Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis

    Andreas Kerschbaumer1, Harald Herkner2, Josef S. Smolen3 and Daniel Aletaha4, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 4Medical University of Vienna, Vienna, Austria

    Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
  • Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

    Song-Chou Hsieh1, Yi-Hsing Chen2, Wei-Sheng Chen3, Wen-Chan Tsai4, Jui-Chieh Hu5, Hsiang-Cheng Chen6, Jack Mardekian7 and Chacun Lai8, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taichung Veterans General Hospital, Taichung City, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 6National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, 7Pfizer Global Biometrics & Data Management, NY, NY, 8Pfizer PFE Limited, New Taipei, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
  • Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting

    Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study

    Hilde B Hammer1, Lars Fritjof Karoliussen2, Lene Terslev3, Espen A. Haavardsholm1, Tore Kvien4 and Till Uhlig5, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, 4RAID working group for EULAR, Zurich, Switzerland, 5Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose:  Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
  • Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting

    Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

    Caitrin Coffey1, Michael Richter1, Cynthia S. Crowson2, Matthew J. Koster3, Kenneth J. Warrington4 and Ashima Makol3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
  • Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Yeong Wook Song6, Yi-Hsing Chen7, Mitsuhiro Rokuda8, Hiroyuki Izutsu8, Satoshi Ushijima8, Yuichiro Kaneko8, Teruaki Shiomi8 and Emi Yamada8, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Nagasaki University, Nagasaki, Japan, 4University of Tokyo, Tokyo, Japan, 5Yokohama City University, Yokohama, Japan, 6Seoul National University Hospital, Seoul, Korea, Republic of (South), 7Taichung Veterans General Hospital, Taichung City, Taiwan, 8Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
  • Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate

    Tsutomu Takeuchi1, Yoshiya Tanaka2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Mitsuhiro Rokuda6, Hiroyuki Izutsu6, Satoshi Ushijima6, Yuichiro Kaneko6, Teruaki Shiomi6 and Emi Yamada6, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Nagasaki University, Nagasaki, Japan, 4University of Tokyo, Tokyo, Japan, 5Yokohama City University, Yokohama, Japan, 6Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
  • Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program

    Stanley Cohen1, Yoshiya Tanaka2, Xavier Mariette3, Jeffrey R. Curtis4, Eun Bong Lee5, Peter Nash6, Kevin Winthrop7, Christina Charles-Schoeman8, Lisy Wang9, Connie Chen10, Kenneth Kwok10, Pinaki Biswas10, Andrea Shapiro11, Ann Madsen10 and Jürgen Wollenhaupt12, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Paris-Sud University, Le Kremlin Bicêtre, France, 4University of Alabama at Birmingham, Birmingham, AL, 5Seoul National University, Seoul, Korea, Republic of (South), 6University of Queensland, Brisbane, Australia, 7Oregon Health and Science University, Portland, OR, 8University of California, Los Angeles, CA, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY, 11Pfizer Inc, Peapack, NJ, 12Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
  • Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting

    Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

    Jeffrey R. Curtis1, Jürgen Wollenhaupt2, Katerina Chatzidionysiou3, Sander W. Tas4, Lisy Wang5, Harry Shi6, María Montoro7, Petra Neregård8, Palle Dahl9 and Vassilis Tsekouras10, 1University of Alabama at Birmingham, Birmingham, AL, 2Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Madrid, Spain, 8Pfizer Inc, Stochholm, Sweden, 9Pfizer Inc, Ballerup, Denmark, 10Pfizer Inc, Athens, Greece

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
  • Abstract Number: 548 • 2017 ACR/ARHP Annual Meeting

    LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis

    Matthew Loza1, Androniki Bili2, Shruti Daga3, Kurt Brown4, Jennifer Gilbride5, Bidisha Dasgupta2, Benjamin Hsu2 and Iain B. McInnes6, 1Janssen Research & Development, LLC, Springhouse, PA, 2Janssen Research & Development, LLC, Spring House, PA, 3GlaxoSmithKline, Uxbridge, United Kingdom, 4GlaxoSmithKline, Collegeville, PA, 5Sum of Squares Ltd, Hertfordshire, United Kingdom, 6University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in RA in the phase…
  • Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting

    The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study

    Ingrid Louw1, Alan J. Kivitz2, Tsutomu Takeuchi3, Yoshiya Tanaka4, Satoshi Nakashima5, Jennifer Hodge6, Hong Tang6, Paula O'Connor6 and Barbara Finck6, 1Panorama Medical Centre, Cape Town, South Africa, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3Keio University School of Medicine, Tokyo, Japan, 4School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 5Daiichi Sankyo, Tokyo, Japan, 6Coherus BioSciences, Inc., Redwood City, CA

    Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
  • Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting

    Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials

    Bidisha Dasgupta1, Matthew Loza1, Androniki Bili1, Shruti Daga2, Kurt Brown3, Jennifer Gilbride4, Benjamin Hsu1 and Iain B. McInnes5, 1Janssen Research & Development, LLC, Spring House, PA, 2GlaxoSmithKline, Uxbridge, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Sum of Squares Ltd, Hertfordshire, United Kingdom, 5University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…
  • Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting

    Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

    Mark C. Genovese1, Josephine Glover2, Nobuhito Matsunaga3, Diane Chisholm4 and Rieke Alten5, 1Stanford University Medical Center, Palo Alto, CA, 2Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, 3Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, 4Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, 5University Medicine Berlin, Berlin, Germany

    Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
  • Abstract Number: 551 • 2017 ACR/ARHP Annual Meeting

    Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-

    Kosuke Ebina1, Makoto Hirao2, Motomu Hashimoto3, Moritoshi Furu4, Wataru Yamamoto5, Ryota Hara6, Takanori Fujimura6, Toru Hirano7, Shuzo Yoshida8, Koji Nagai8, Hideki Amuro9, Yonsu Son9, Akira Onishi10, Kengo Akashi11, Masaki Katayama12, Keiichi Yamamoto13 and Hideki Yoshikawa14, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Kurashiki Sweet Hospital, Okayama, Japan, 6The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan, 7Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 8Osaka Medical College, Osaka, Japan, 9Kansai Medical University, Osaka, Japan, 10Kobe University Graduate School of Medicine, Kobe, Japan, 11Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, 12Osaka Red Cross Hospital, Osaka, Japan, 13Osaka City University, Osaka, Japan, 14Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose:  More than 4 years have passed since 7 biologics became available for patients with rheumatoid arthritis (RA) in Japan, still lack reliable evidence in…
  • Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting

    Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Paul Studenic1, Farideh Alasti2, Daniel Aletaha3, Josef S. Smolen1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology